{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:31:59Z","timestamp":1785529919181,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ20B020001"],"award-info":[{"award-number":["LQ20B020001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY20B020003"],"award-info":[{"award-number":["LY20B020003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bioorg.2021.105342","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T01:45:59Z","timestamp":1631324759000},"page":"105342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPAR\u03b3"],"prefix":"10.1016","volume":"116","author":[{"given":"Juan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Cheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105342_b0005","doi-asserted-by":"crossref","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43(2): 487-493. http:\/\/dx.doi.org\/10.2337\/dci19-0066.","DOI":"10.2337\/dci19-0066"},{"issue":"15","key":"10.1016\/j.bioorg.2021.105342_b0010","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105342_b0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2021.105342_b0020","first-page":"55","article-title":"Structural characterization and hypoglycemic activity of Trichosanthes peel polysaccharide. Lwt","volume":"70","author":"Chen","year":"2016","journal-title":"Food Science & Technology"},{"key":"10.1016\/j.bioorg.2021.105342_b0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105342_b0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ajo.2011.06.022","article-title":"Revisiting diabetes 2000: challenges in establishing nationwide diabetic retinopathy prevention programs","volume":"152","author":"Hazin","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"21","key":"10.1016\/j.bioorg.2021.105342_b0035","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1039\/D0CS00304B","article-title":"Electrochemical glucose sensors in diabetes management: an updated review (2010\u20132020)","volume":"49","author":"Teymourian","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2021.105342_b0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.inffus.2021.02.015","article-title":"Risk Prediction of Diabetes: Big data mining with fusion of multifarious physical examination indicators","volume":"75","author":"Yang","year":"2021","journal-title":"Information Fusion"},{"issue":"22","key":"10.1016\/j.bioorg.2021.105342_b0045","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1016\/j.bmc.2004.08.031","article-title":"Synthesis and anti-hyperglycemic activity profiles of novel thiazolidinedione derivatives","volume":"12","author":"Bhat","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105342_b0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jscs.2012.10.010","article-title":"Design and synthesis of novel thiazolidine- 2,4-diones as hypoglycemic agents","volume":"20","author":"Datar","year":"2016","journal-title":"J.Saudi Chem. Soc"},{"issue":"19","key":"10.1016\/j.bioorg.2021.105342_b0055","doi-asserted-by":"crossref","first-page":"14095","DOI":"10.1039\/C4RA16903D","article-title":"Discovery of novel 1,3,5-triazine-thiazolidine- 2,4-diones as dipeptidyl peptidase-4 (DPP-4) inhibitor targeting S1 pocket for the treatment of type 2 diabetes along with antibacterial activity","volume":"5","author":"Srivastava","year":"2015","journal-title":"RSC Adv."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105342_b0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/10426507.2020.1737061","article-title":"Synthesis and anti-diabetic activity evaluation of phosphonates containing thiazolidinedione moiety","volume":"195","author":"Sujatha","year":"2020","journal-title":"Phosphorus Sulfur and Silicon and the Related Elements"},{"issue":"2189","key":"10.1016\/j.bioorg.2021.105342_b0065","first-page":"1","article-title":"The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development","volume":"19","author":"Fan","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105342_b0070","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14756366.2019.1608197","article-title":"Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers","volume":"34","author":"Huiying","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105342_b0075","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejmech.2016.12.020","article-title":"Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present","volume":"126","author":"Yasmin","year":"2017","journal-title":"European J. Med. Chem"},{"key":"10.1016\/j.bioorg.2021.105342_b0080","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejmech.2017.02.031","article-title":"Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship","volume":"129","author":"Naim","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105342_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14776-0","article-title":"Novel Benzylidene Thiazolidinedione Derivatives as Partial PPAR\u03b3 Agonists and their Antidiabetic Effects on Type 2 Diabetes","volume":"7","author":"Yasmin","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105342_b0090","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/acs.jmedchem.1c00491","article-title":"Thiazolidinedione \u201cMagic Bullets\u201d Simultaneously Targeting PPAR\u03b3 and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects","volume":"64","author":"Tilekar","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105342_b0095","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"and ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"New England J. Med"},{"issue":"8","key":"10.1016\/j.bioorg.2021.105342_b0100","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"RUBENSTRUNK","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105342_b0105","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1039\/D0NJ05649A","article-title":"Design, synthesis, in silico molecular modelling studies and biological evaluation of novel indole-thiazolidinedione hybrid analogues as potential pancreatic lipase inhibitors","volume":"45","author":"George","year":"2021","journal-title":"New J. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105342_b0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4236\/ojmc.2020.102003","article-title":"Targeting PPAR \u03b3 Receptor Using New Phosphazene Derivative Containing Thiazolidinedione: Design, Synthesis, and Glucose Uptake","volume":"10","author":"Neyadi","year":"2020","journal-title":"Open Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2021.105342_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1069718","article-title":"Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs","volume":"2017","author":"Thangavel","year":"2017","journal-title":"International Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/j.bioorg.2021.105342_b0120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.5483\/BMBRep.2014.47.11.174","article-title":"Revisiting PPAR\u03b3 as a target for the treatment of metabolic disorders","volume":"47","author":"Choi","year":"2014","journal-title":"Bmb Reports"},{"issue":"16","key":"10.1016\/j.bioorg.2021.105342_b0125","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.2174\/0929867327666200716113136","article-title":"Role of Peroxisome Proliferator-Activated Receptor Gamma (PPAR\u03b3)in Different Disease States: Recent Updates","volume":"28","author":"Mal","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2021.105342_b0130","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1021\/jm501155f","article-title":"Peroxisome Proliferator-Activated Receptor\u03b3 (PPAR\u03b3) and Ligand Choreography: Newcomers Take the Stage","volume":"58","author":"Garcia-Vallv\u00e9","year":"2015","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105342_b0135","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1021\/acs.jmedchem.6b01727","article-title":"Structure-Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPAR\u03b3-Targeted Antidiabetics","volume":"60","author":"Frkic","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105342_b0140","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s12272-020-01235-0","article-title":"LJ-529, a partial peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist and adenosine A3 receptor agonist, ameliorates elastase-induced pulmonary emphysema in mice","volume":"43","author":"Boo","year":"2020","journal-title":"Archives of Pharmacal Research"},{"issue":"9","key":"10.1016\/j.bioorg.2021.105342_b0145","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s12272-010-0912-z","article-title":"Quantification of a novel PPAR\u03b3 partial agonist (S)-2-ethoxy-3-(4-{3-methyl-5-[4-(3-methyl-isoxazol-5-yl)-phenyl] thiophen- 2-ylmethoxy-phenyl)-propionic acid (PAM-1616) in rat plasma using liquid chromatography-tandem mass spectrometry","volume":"33","author":"Chae","year":"2010","journal-title":"Archives of Pharmacal Research"},{"key":"10.1016\/j.bioorg.2021.105342_b0150","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejmech.2016.12.020","article-title":"Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.","volume":"126","author":"Yasmin","year":"2017","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105342_b0185","first-page":"e36297","article-title":"Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) gammar Activators and Pan-PPAR Partial Agonists.","volume":"7","author":"Marcelo","year":"2021","journal-title":"Plos one"},{"key":"10.1016\/j.bioorg.2021.105342_b0155","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","article-title":"Partial agonists activate PPAR gamma using a helix 12 independent mechanism","volume":"15","author":"Bruning","year":"2007","journal-title":"Structure"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105342_b0160","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/08820139.2019.1586917","article-title":"Analysis of Inflammatory Gene Expression Profile of Peripheral Blood Leukocytes in Type 2 Diabetes","volume":"48","author":"Inayat","year":"2019","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.bioorg.2021.105342_b0165","doi-asserted-by":"crossref","first-page":"108928","DOI":"10.1016\/j.cbi.2019.108928","article-title":"Isoniazid promotes the anti-inflammatory response in zebrafish associated with regulation of the PPAR\u03b3\/NF-\u03baB\/AP-1 pathway","volume":"316","author":"Zhang","year":"2020","journal-title":"Chemico-Biological Interactions"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105342_b0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0165-6147(00)01559-5","article-title":"PPAR-\u03b3 agonists: Therapeutic role in diabetes, inflammation and cancer","volume":"21","author":"Murphy","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105342_b0175","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The Many Faces of PPAR\u03b3","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bioorg.2021.105342_b0180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol. Metab."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:29:38Z","timestamp":1758616178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821007197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":37,"alternative-id":["S0045206821007197"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105342","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPAR\u03b3","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105342"}}